Anlotinib is an oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) that is used to treat advanced cancer.

It works by inhibiting the tyrosine kinase activity of several receptor tyrosine kinases (RTKs), including VEGF receptors, c-Kit, PDGFR-α, and fibroblast growth factor receptors. has a broad range of inhibitory effects on tumor angiogenesis and growth. 

In combination with PD – L1 in addition to etoposide/platinum had a 7.4 month median improvement in overall survival compared with chemotherapy plus placebo in small cell lung cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *